Literature DB >> 25931122

MicroRNA-193a-3p Reduces Intestinal Inflammation in Response to Microbiota via Down-regulation of Colonic PepT1.

Xin Dai1, Xi Chen2, Qun Chen2, Lei Shi2, Hongwei Liang2, Zhen Zhou2, Qian Liu1, Wenjing Pang1, Dongxia Hou2, Cheng Wang2, Ke Zen2, Yaozong Yuan3, Chen-Yu Zhang4, Lu Xia5.   

Abstract

Intestinal inflammation is characterized by epithelial disruption, leading to the loss of barrier function, recruitment of immune cells, and host immune responses to gut microbiota. PepT1, a di/tripeptide transporter that uptakes bacterial products, is up-regulated in inflamed colon tissue, which implies its role in bacterium-associated intestinal inflammation. Although microRNA (miRNA)-mediated gene regulation has been found to be involved in various processes of inflammatory bowel disease (IBD), the biological function of miRNAs in the pathogenesis of IBD remains to be explored. In this study we detected miRNA expression patterns in colon tissues during colitis and investigated the mechanism underlying the regulation of colonic PepT1 by miRNAs. We observed an inverse correlation between PepT1 and miR-193a-3p in inflamed colon tissues with active ulcerative colitis, and we further demonstrated that miR-193a-3p reduced PepT1 expression and activity as a target gene and subsequently suppressed the NF-κB pathway. Intracolonic delivery of miR-193a-3p significantly ameliorated dextran sodium sulfate-induced colitis, whereas the overexpression of colonic PepT1 via PepT1 3'-untranslated region mutant lentivirus vector abolished the anti-inflammatory effect of miR-193a-3p. Furthermore, antibiotic treatment eliminated the difference in the dextran sodium sulfate-induced inflammation between the presence and absence of miR-193a-3p. These findings suggest that miR-193a-3p regulation of PepT1 mediates the uptake of bacterial products and is a potent mechanism during the colonic inflammation process. Overall, we believe miR-193a-3p may be a potent regulator of colonic PepT1 for maintaining intestinal homeostasis.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  gene regulation; inflammatory bowel disease (IBD); microRNA (miRNA); mucosal immunology; peptide transport

Mesh:

Substances:

Year:  2015        PMID: 25931122      PMCID: PMC4481212          DOI: 10.1074/jbc.M115.659318

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  Abnormal activation of transcription factor NF-kappaB involved in steroid resistance in chronic inflammatory bowel disease.

Authors:  H Bantel; W Domschke; K Schulze-Osthoff; B Kaskas; M Gregor
Journal:  Am J Gastroenterol       Date:  2000-07       Impact factor: 10.864

Review 2.  MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship.

Authors:  Amy E Pasquinelli
Journal:  Nat Rev Genet       Date:  2012-03-13       Impact factor: 53.242

Review 3.  Inflammatory diseases: is ubiquitinated NEMO at the hub?

Authors:  Kimberly A Burns; Fabio Martinon
Journal:  Curr Biol       Date:  2004-12-29       Impact factor: 10.834

Review 4.  The oligopeptide transporter (Pept-1) in human intestine: biology and function.

Authors:  S A Adibi
Journal:  Gastroenterology       Date:  1997-07       Impact factor: 22.682

5.  PepT1-mediated fMLP transport induces intestinal inflammation in vivo.

Authors:  Marion Buyse; Annick Tsocas; Francine Walker; Didier Merlin; Andre Bado
Journal:  Am J Physiol Cell Physiol       Date:  2002-12       Impact factor: 4.249

6.  fMLP induces Hsp27 expression, attenuates NF-kappaB activation, and confers intestinal epithelial cell protection.

Authors:  Ryan M Carlson; Stephan R Vavricka; Jyrki J Eloranta; Mark W Musch; Donna L Arvans; Keri A Kles; Margaret M Walsh-Reitz; Gerd A Kullak-Ublick; Eugene B Chang
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2006-12-21       Impact factor: 4.052

7.  Chemically induced mouse models of intestinal inflammation.

Authors:  Stefan Wirtz; Clemens Neufert; Benno Weigmann; Markus F Neurath
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

8.  Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease.

Authors:  L Gorelik; R A Flavell
Journal:  Immunity       Date:  2000-02       Impact factor: 31.745

9.  PepT1 mediates colon damage by transporting fMLP in rats with bowel resection.

Authors:  Bin Shi; Desheng Song; Hua Xue; Ning Li; Jieshou Li
Journal:  J Surg Res       Date:  2006-09-01       Impact factor: 2.192

10.  Long-term effect of leptin on H+-coupled peptide cotransporter 1 activity and expression in vivo: evidence in leptin-deficient mice.

Authors:  Patrick Hindlet; André Bado; Robert Farinotti; Marion Buyse
Journal:  J Pharmacol Exp Ther       Date:  2007-07-10       Impact factor: 4.030

View more
  33 in total

Review 1.  MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy.

Authors:  Ai-Ming Yu; Ye Tian; Mei-Juan Tu; Pui Yan Ho; Joseph L Jilek
Journal:  Drug Metab Dispos       Date:  2015-11-13       Impact factor: 3.922

2.  Characterization of Extracellular Vesicles from Entamoeba histolytica Identifies Roles in Intercellular Communication That Regulates Parasite Growth and Development.

Authors:  Manu Sharma; Pedro Morgado; Hanbang Zhang; Gretchen Ehrenkaufer; Dipak Manna; Upinder Singh
Journal:  Infect Immun       Date:  2020-09-18       Impact factor: 3.441

Review 3.  Functional role and therapeutic targeting of microRNAs in inflammatory bowel disease.

Authors:  Artin Soroosh; Marina Koutsioumpa; Charalabos Pothoulakis; Dimitrios Iliopoulos
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-11-16       Impact factor: 4.052

Review 4.  Function, Regulation, and Pathophysiological Relevance of the POT Superfamily, Specifically PepT1 in Inflammatory Bowel Disease.

Authors:  Emilie Viennois; Adani Pujada; Jane Zen; Didier Merlin
Journal:  Compr Physiol       Date:  2018-03-25       Impact factor: 9.090

Review 5.  miRNAs in gastrointestinal diseases: can we effectively deliver RNA-based therapeutics orally?

Authors:  A K M Nawshad Hossian; Gerardo G Mackenzie; George Mattheolabakis
Journal:  Nanomedicine (Lond)       Date:  2019-11-18       Impact factor: 5.307

6.  Long non-coding RNA NEAT1 predicts elevated chronic obstructive pulmonary disease (COPD) susceptibility and acute exacerbation risk, and correlates with higher disease severity, inflammation, and lower miR-193a in COPD patients.

Authors:  Xiaoyan Ming; Weizhe Duan; Wei Yi
Journal:  Int J Clin Exp Pathol       Date:  2019-08-01

7.  MicroRNA-31-3p Is Involved in Substance P (SP)-Associated Inflammation in Human Colonic Epithelial Cells and Experimental Colitis.

Authors:  Kai Fang; Ivy Ka Man Law; David Padua; Aristea Sideri; Vanessa Huang; Christopher G Kevil; Dimitrios Iliopoulos; Charalabos Pothoulakis
Journal:  Am J Pathol       Date:  2017-12-16       Impact factor: 4.307

8.  miRNA-133a-UCP2 pathway regulates inflammatory bowel disease progress by influencing inflammation, oxidative stress and energy metabolism.

Authors:  Xi Jin; Dong Chen; Ruo-Heng Zheng; Hong Zhang; Yi-Peng Chen; Zun Xiang
Journal:  World J Gastroenterol       Date:  2017-01-07       Impact factor: 5.742

Review 9.  MicroRNAs in mucosal inflammation.

Authors:  Viola Neudecker; Xiaoyi Yuan; Jessica L Bowser; Holger K Eltzschig
Journal:  J Mol Med (Berl)       Date:  2017-07-20       Impact factor: 4.599

Review 10.  MicroRNAs in intestinal barrier function, inflammatory bowel disease and related cancers-their effects and therapeutic potentials.

Authors:  Esmerina Tili; Jean-Jacques Michaille; Victoria Piurowski; Brooke Rigot; Carlo M Croce
Journal:  Curr Opin Pharmacol       Date:  2017-11-15       Impact factor: 5.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.